In July, the US Food and Drug Administration (FDA) approved a new blood-based test to screen for colorectal cancer (CRC). The FDA's approval of Shield (Guardant Health) marks a notable achievement, as ...
Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...
New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...
BRISBANE, Calif., May 27, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, welcomes the inclusion of blood-based testing in the American Cancer ...
BRISBANE, Calif., July 9, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, today announced favorable results from its pivotal clinical ...
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
Colorectal cancer screening preferences differ across underserved populations, suggesting that aligning screening options with patient preferences may help improve screening uptake and adherence. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results